Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Sodium phenylbutyrate

Phase 2

JJerry Vockley, MD, PhD

Sodium phenylbutyrate is one of 2 therapeutic programs targeting Medium-chain Acyl-CoA Dehydrogenase Deficiency. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[2][1]

Indication

Medium-Chain Acyl-Coa Dehydrogenase DeficiencySuspended

Medium-Chain Acyl-Coa Dehydrogenase DeficiencyPhase 2

Suspended

Competition

Competitive Landscape

1 competitor in Medium-Chain Acyl-Coa Dehydrogenase Deficiency

#DrugCompanyPhaseTrials

Dojolvi

Sodium phenylbutyrate

JJerry Vockley, MD, PhD

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Medium-chain Acyl-CoA Dehydrogenase Deficiency1 trial

A Phase 2, Open-Label, Fixed Dose Study to Evaluate the Use of Sodium Phenylbutyrate (ACER-001) in the Treatment of Pediatric and Adult Patients With MCAD Deficiency Caused by the Common ACADM c.985 A>G (K304E) Mutation

Suspended·JJerry Vockley, MD, PhD·Phase 2·NCT06069375·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sodium phenylbutyrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sodium phenylbutyrate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Jerry Vockley, MD, PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: JJerry Vockley, MD, PhD

Related News